**Ampliphi Biosciences (NYSEAMERICAN:APHB) Announces Positive Results from Phase 2 Tailwind Study**

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) has recently shared significant updates regarding its Phase 2 Tailwind study results for inhaled AP-PA02 in non-cystic fibrosis bronchiectasis subjects with chronic pulmonary Pseudomonas aeruginosa infection. The press release issued by the company on December 19, 2024, unveiled the positive outcomes of the study.

In addition to these results, Armata Pharmaceuticals disclosed an updated corporate presentation dated December 19, 2024, available for viewing on their website. This new Corporate Presentation, featured as Exhibit 99.2, replaces the previously dated version from November 15, 2024, and aims to provide investors with the latest insights into the company’s advancements.

The Corporate Presentation shares a summarized overview of the company’s progress, intended to supplement information disclosed in Armata Pharmaceuticals’ Securities and Exchange Commission (SEC) filings and other public communications. It emphasizes that the company reserves the right to periodically update this information and is committed to complying with federal securities laws as necessary.

This disclosure corresponds to Regulation FD Disclosure, indicating the company’s endeavor to keep stakeholders informed about its developments. The content included in the Corporate Presentation alongside the press release is not classified as “filed” per Section 18 of the Securities Exchange Act of 1934 or integrated by reference into any registration statements or documents under the Securities Act of 1933.

Armata Pharmaceuticals displayed its commitment to transparency by furnishing the Corporate Presentation and press release. However, the firm clarified that no implications about the materiality of this information should be drawn solely from its disclosure in this Form 8-K.

The submitted 8-K also outlined the company’s financial statements and exhibits associated with the disclosure. Armata Pharmaceuticals’ strong focus on regulatory compliance, manufacturing excellence, and continued clinical advancements highlight its dedication to pioneering phage-based therapeutics in addressing antibiotic resistance and enhancing patient care.

This latest update underscores the company’s strategic drive towards pivotal studies, potential regulatory approvals, and its roadmap for commercial success. With a diversified clinical pipeline and robust manufacturing capabilities, Armata Pharmaceuticals aims to sustain its leadership in developing phage-based anti-infectives.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Ampliphi Biosciences’s 8K filing here.

Ampliphi Biosciences Company Profile

AmpliPhi Biosciences Corporation, a biotechnology company, focuses on the development of therapies for antibiotic-resistant infections using bacteriophage-based technology. The company is involved in developing AB-SA01 for the treatment of staphylococcus aureus (S. aureus) infections; and AB-PA01 for the treatment of pseudomonas aeruginosa (P.